Therapeutic Developments for Relapsed/Refractory Multiple Myeloma: Other Novel Agents With New Targets

Download these slides to review expert insights on novel agents with new targets for patients with relapsed, refractory MM.
person default
Prof. Dr. med. Katja Weisel
Format: Microsoft PowerPoint (.ppt)
File Size: 731 KB
Released: July 20, 2020

Acknowledgements

Provided by Clinical Care Options, LLC, in partnership with Clinical Care Options Global B.V.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Related Content

Experts answer FAQ on key issues in the management of multiple myeloma

Brian G.M. Durie, MD Shaji Kumar, MD Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD Released: January 27, 2021

From Clinical Care Options, download slides reviewing the integration of CAR T-cell therapy into community care

Michael R. Bishop, MD Jae H. Park, MD Released: January 26, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy into community care

Michael R. Bishop, MD Jae H. Park, MD Released: January 26, 2021

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue